Condition: Rhabdomyosarcoma, Child · Sponsor: Sun Yat-sen University
This multicenter, randomized, controlled, open-label, prospective clinical trial was designed to evaluate the efficacy and safety of doxorubicin hydrochloride liposome injection in combination with irinotican (AI regimen) versus VIT regimen in the treatment of relapsed and refractory pediatric rhabdomyosarcoma.
This description comes directly from the study's public registry record.
Yzhuo Zhang, PhD · 020-87342460 · zhangyzh@sysucc.org.cn
Juan Wang · 02087343598 · wangjuan@sysucc.org.cn
Always discuss trial participation with your own doctor first.
| Sun Yat-Sen University Cancer Center | Guangzhou, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05457829